Skip to main content

Table 2 Clinical features of SSc patientsa

From: Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide

Patient characteristics Patients Controls
Caucasian males, n 3 9
Caucasian females, n 4 12
African-American males, n 1 2
African-American females, n 4 2
Asian females, n 1 1
Smokers, n 1 0
Former smokers, n 3 0
Mean age ± SD, years (range) 54.6 ± 9.8 (39 to 75) 43.7 ± 9.4 (22 to 57)
Disease: limited cutaneous, n 0 Not applicable
   Diffuse cutaneous 9 Not applicable
   Overlap 4 Not applicable
Disease duration, years: mean ± SD (range) 9.4 ± 6.6 (1 to 22) Not applicable
Pulmonary involvement (ILD) 13 of 13 (100%) Not applicable
Pulmonary Hypertension 5 of 13 (38.5%) Not applicable
GI involvement 12 of 13 (92.3%) Not applicable
Cardiac involvement 7 of 13 (53.8%) Not applicable
Renal involvement 0 of 13 (0%) Not applicable
Autoantibodies: ANA+ 11 of 11 (100%) Not applicable
   Scl-70+ 4 of 11 (36%) Not applicable
   Anticentromere 0 of 10 (0%) Not applicable
  1. aSSc, systemic sclerosis; SD, standard deviation; ILD, interstitial lung disease; GI, gastrointestinal; ANA, antinuclear antibody.